Bristol-Myers Squibb reports positive melanoma trial data for Opdivo

Bristol-Myers Squibb has announced the results of a phase III clinical trial that demonstrates the strong performance of its drug Opdivo in the treatment of melanoma.

The company has reported the first overall survival data from the CheckMate -067 clinical trial, which is assessing the performance of Opdivo in combination with Yervoy and as a monotherapy compared to Yervoy alone.

It was shown that Opdivo in combination with Yervoy and as a monotherapy reduced the risk of death by 45 percent and 37 percent respectively compared with Yervoy alone in patients with previously untreated advanced melanoma.

Meanwhile, the updated safety data reported in this analysis was consistent with previously reported experience, with no cumulative toxicity noted or new safety signals identified. 

Dr Vicki Goodman, development lead for melanoma and genitourinary cancers at Bristol-Myers Squibb, said: "This first disclosure of overall survival data from CheckMate -067 helps to advance our understanding of the potential longer term benefits of Opdivo in combination with Yervoy in advanced melanoma, a cancer that historically has been difficult to treat."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.